10.36
Promis Neurosciences Inc Aktie (PMN) Neueste Nachrichten
PMN Q1 2026 Earnings: Narrower-than-expected Loss; Stock Gains on Pipeline ProgressPretax Income Report - Newser
Executive at ProMIS (PMN) receives 18,167 stock options expiring 2036 - Stock Titan
ProMIS Neurosciences (PMN) director receives 16,500 stock options grant - Stock Titan
ProMIS Neurosciences (PMN) CDO awarded 50,000 stock options - Stock Titan
Director at ProMIS Neurosciences (PMN) receives new option grants as board compensation - Stock Titan
PMN Technical Analysis | Trend, Signals & Chart Patterns | PROMIS NEUROSCIENCES INC (NASDAQ:PMN) - ChartMill
Analysts’ Top Healthcare Picks: ProMIS Neurosciences (PMN), Evolent Health (EVH) - The Globe and Mail
Great Point, Dr. Jay and Nordahl report 9.99% stake in PROMIS (PMN) - Stock Titan
Wellington Group discloses 895,871-share holding in ProMIS (PMN) - Stock Titan
ProMIS Neurosciences Inc. Q1 2026 Financial Results, Forward-Looking Statements, and Risk Factors Overview - Minichart
TradingKey - TradingKey
ProMIS Neurosciences Releases Q1 2026 Financial Results - AlphaStreet
ProMIS Neurosciences Reports Q1 2026 Results, Advances Alzheimer’s PMN310 Trial and Secures $175M Financing - Minichart
ProMIS Neurosciences (PMN) Q1 2026 Earnings: EPS N/A, Revenue N/ - GuruFocus
ProMIS (PMN) Targets Alzheimer's Treatment with Promising Trial and Funding - GuruFocus
ProMIS Neurosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
ProMIS Neurosciences Inc. Q1 2026: Net income $(8.24M), Diluted EPS $(1.26) — 10-Q Summary - TradingView
ProMIS Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] ProMIS Neurosciences Inc. Quarterly Earnings Report - Stock Titan
ProMIS Neurosciences (Nasdaq: PMN) boosts cash with $175M financing and advances PMN310 - Stock Titan
ProMIS Neurosciences Inc. Closes PIPE Financing of Up to $175 Million to Support Alzheimer's Disease Clinical Trial - Quiver Quantitative
Alzheimer's trial fully enrolled as ProMIS funds work through 2027 - Stock Titan
ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights - ChartMill
ProMIS Neurosciences (PMN) owners report 181,632 shares (2.0%) in 13G/A amendment - Stock Titan
Insider Purchase: Director at $PMN Buys 4,000 Shares - Moomoo
ProMIS Neurosciences to execute 1-for-25 reverse stock split - MSN
ProMIS Neurosciences Shares Advance After New Data Supports Alzheimer’s Trial Strategy - MSN
PMN Price Today: ProMIS Neurosciences Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Director Kirwin’s entity buys 4,000 ProMIS (PMN) shares at $11.33 - Stock Titan
PMN ProMIS Neurosciences Inc. Common Shares (ON) posts wider than expected Q4 2025 loss but still notches small share price gain today.Equity Raise - UBND thành phố Hải Phòng
ProMIS (PMN) Stock: Is It Overpriced in Market (Drifts Lower) 2026-04-18Fast Rising Stocks - Cổng thông tin điện tử tỉnh Lào Cai
CEO Neil Warma to outline Alzheimer’s trial timeline at Apr. 21 event - Stock Titan
Winners Losers: Is ProMIS Neurosciences Inc stock a hidden gem2026 Breakouts & Breakdowns & Weekly High Return Forecasts - baoquankhu1.vn
What events could move ProMIS (PMN) Stock next | Price at $12.95, Up 2.78%Flat Correction - Newser
Major holders and board changes in ProMIS Neurosciences (PMN) 2026 proxy statement - Stock Titan
Multiple System Atrophy Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, And FDA Approvals By Delveinsight Neuramedy, Promis Neurosciences, Enterin Inc., Nippon Chemiphar - Mena FN
PMN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Can ProMIS Neurosciences Inc continue delivering strong returns2026 Analyst Calls & Fast Gaining Stock Reports - baoquankhu1.vn
Analysis Recap: Can ProMIS Neurosciences Inc continue delivering strong returnsQuarterly Profit Report & Daily Technical Forecast Reports - baoquankhu1.vn
How does currency impact ProMIS (PMN) Stock | Price at $10.88, Down 0.73%Shared Buy Zones - Newser
ProMIS Neurosciences Shares Plunge Amid Critical Clinical Trial Phase - AD HOC NEWS
Janus Henderson (PMN) discloses 14.4% holding in PROMIS Neurosciences - Stock Titan
Is ProMIS (PMN) Stock Overpriced Now | Price at $11.05, Down 11.67%Growth Investing - Newser
PMN Technical Analysis & Stock Price Forecast - Intellectia AI
Promis Neurosciences (NASDAQ:PMN) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
PMN Faces Selling Pressure: Technical Levels to Watch - Xã Thanh Hà
Weekly Earnings: Will ProMIS Neurosciences Inc stock go up in YEARShare Buyback & Low Drawdown Investment Strategies - baoquankhu1.vn
Aug Volume: How does ProMIS Neurosciences Inc perform in inflationary periods2026 Sentiment & Risk Controlled Swing Alerts - baoquankhu1.vn
ProMIS Neurosciences Inc expected to post a loss of $1.91 a shareEarnings Preview - TradingView
[EFFECT] ProMIS Neurosciences Inc. SEC Filing - Stock Titan
Aug Mood: How cyclical is ProMIS Neurosciences Incs revenue stream2026 Institutional Moves & Low Risk Profit Maximizing Plans - baoquankhu1.vn
ProMIS Neurosciences 2025 Annual Report: Pipeline, Risks, and Strategic Objectives for Alzheimer’s Drug Development - Minichart
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):